熊去氧胆酸对Ⅰ型自身免疫性肝炎的疗效观察

谭友文; 吴建成; 於学军

熊去氧胆酸对Ⅰ型自身免疫性肝炎的疗效观察

详细信息

中图分类号: R575.1
计量
- 文章访问数: 2180
- HTML全文浏览量: 12
- PDF下载量: 1002
- 被引次数: 0
出版历程
- 出版日期: 2004-05-20

Efficacy of ursodeoxycholic acid in the treatment of type Ⅰ autoimmune hepatitis

摘要

摘要: 观察熊去氧胆酸（UDCA）对Ⅰ型自身免疫性肝炎的疗效。随机选取 4 2例Ⅰ型自身免疫性肝炎分为三组 ,分别采用UDCA（A组） ,皮质类固醇激素 +UDCA （B组）和单纯皮质类固醇激素（C组）治疗八周 ,观察患者症状、肝功能及免疫学指标的变化。B组和C组均能较好地改善症状和A组比较有显著差异性（P <0 0 5 ） ,TBil、ALT、γ -GT以及IgGB组和C组均较A组明显改善（P <0 0 5 ） ,B、C组间比较有显著差异（P <0 0 5 ） ;B组产生副作用与C组比较差异显著（P <0 0 5 ）。UDCA与皮质类固醇激素合用能有较好疗效 ,可以减少其使用量及副作用
- 自身免疫性肝炎 /
- 熊去氧胆酸 /
- 皮质类固醇激素
Abstract: To observe the efficacy and safety of ursodeoxycholic acid in the treatment of type Ⅰ autoimmune hepatitis. 42 patients with type Ⅰ autoimmune hepatitis were randomly divided into groups A, B and C. Patients in group A received ursodeoxycholic acid in group B received ursodeoxycholic acid and succinate hydrocortisone in group C received succinate hydrocortison for eight weeks. At the end of treatment the effective in group A was less than that in group B and C, which were significantly differences in all groups (P<0.05) .TBil, TBA, ALT, γ-GT and IgG were lower in group B than in group C (P<0.05) . the effect negative in group B was less than that in group C (P<0.05) . Ursodeoxycholic acid could not replace succinate hydrocortisone in treat type Ⅰ autoimmune hepatitis, but it combined succinate hydrocortisone could decrease the quantities of succinate hydrocortisone.
- autoimmune hepatitis /
- ursodeoxycholic acid /
- succinate hydrocortisone

HTML全文

参考文献(8)

[1]Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31 (5) ∶929-38.

[2]Desmet VJ, Gerber M, Hoofnagle JH. Glassification of chronic hepatitis: diagnosis grading and staging[J]. Hepatology, 1994, 19 (6) ∶1513-20.

[3]Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis[J]. J Gastroenterol Hepatol, 1998, 13 (5) ∶490-5.

[4]Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis[J]. Gastroenterology, 1994, 106 (5) ∶1284-90.

[5]Calmus Y, Guechot J, Podevin P, et al. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes[J]. Hepatology, 1992, 16 (3) ∶719-23.

[6]Nakamura K, Akiyama K, Makino Ⅰ. Effect of long-term ursodeoxycholic acid treatment on serum liver enzyme and serum bile acid metabolism in chronic hepatitis[J]. Nippon Shokakibyo Gakkai Zasshi, 1995, 92 (1) ∶62-71.

[7]Kiso S, Kawata S, Imai Y, et al. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyl transpeptidase levels[J]. J Gastroenterol, 1996, 31 (1) ∶75-80.

[8]Janowitz P, Kratzer W, Wechsler JG. Positive effect of ursodeoxycholic acid on liver enzymes in autoimmune hepatitis with little cutivity pilot study[J].Leber Magen Darm, 1996, 26 (6) ∶310-3.

施引文献

资源附件(0)

访问统计